Angiopoietin-2 May Be Involved in the Resistance to Bevacizumab in Recurrent Glioblastoma

ABSTRACT

Despite encouraging response rate of bevacizumab (BVZ) in recurrent glioblastoma, many patients do not respond to this schedule and most of the responders develop an early relapse. Plasma concentrations of VEGF, PlGF, Ang2, and sTie2 were assessed by ELISA before and during BVZ treatment in seventy patients. Baseline levels of VEGF-A, and PlGF were higher in patients than in healthy volunteers, whereas no difference was found for Ang2, and sTie2. No biomarker at baseline was associated with response, PFS or OS. At recurrence, the authors observed an increase of Ang2 suggesting that Ang2/sTie2 could be involved in the resistance to BVZ.

Keywords:

• Glioblastoma
• bevacizumab
• plasma biomarkers
• Ang2

View correction statement:

Corrigendum

Acknowledgments

Work supported by the Institut National du Cancer (INCa). C.C. was supported by the Association pour la Recherche sur les Tumeurs Cérébrales (ARTC). The authors are also grateful to the Association pour la Recherche contre le Cancer (ARC) for financial support.

Declaration of interest

The authors report no disclosures.

Supplemental material available online

Supplemental Tables S1-S6